Capital Markets · November 12, 2026

Vesalius Longevity Labs Commences Trading Today on the Canadian Securities Exchange Under the Symbol “VLAB”

Vesalius Longevity Labs Inc. (CSE: VLAB) commenced trading on the Canadian Securities Exchange under the symbol “VLAB” today, November 12, 2026.

← Back to News & Resources

Vancouver, BC & Scottsdale, AZ - November 12, 2026 – Vesalius Longevity Labs Inc. (“Vesalius” or the “Company”) (CSE: VLAB) is pleased to announce that it will commence trading on the Canadian Securities Exchange (“CSE”) under the symbol “VLAB” today, November 12, 2026.

“Today marks an important milestone for Vesalius Labs, and I want to sincerely thank our Board of Directors, our entire team, and our shareholders and stakeholders for their support and guidance throughout our journey so far,” said Dr. Pradeep Albert, MD, CEO of Vesalius Labs. “We believe the future is longevity and wellness. As one of the first publicly traded companies in the sector, Vesalius is well positioned to become a leading global brand, backed by science and quality. Peptides are one of the fastest-moving areas in longevity, and we are building the whole path from lab to consumer. That includes Made-in-the-USA peptide APIs under our Peptual® brand, a doctor-led model that connects licensed providers with patients, and AI-powered tools that make care more personalized. Commencing trading on the CSE gives us a strong platform to help accelerate that vision, and we look forward to an exciting road ahead.”

Additional information on the Company and the business of Vesalius can be found in the Company’s Listing Statement dated November 9, 2026 as filed on SEDAR+ at www.sedarplus.ca.

About Vesalius

Vesalius Longevity Labs (CSE: VLAB), is a longevity science and regenerative health platform focused on being the trusted seed-to-brand partner across the consumer journey for peptide therapeutics, biologics and preventative healthcare. Vesalius operates a scalable B2Doctor2Consumer ecosystem designed to support healthcare providers and telehealth infrastructure. Vesalius will manufacture under its Peptual® brand “Made-in-the-USA” peptide APIs (active pharmaceutical ingredients) for domestic and international compounding supply chains. Vesalius’s expanding ecosystem includes regenerative medicine, multi-faceted compounding pharmacy initiatives, biologics partnerships and advanced AI-powered technologies designed to support the future of personalized health and wellness.

Investors interested in learning more about Vesalius Longevity Labs are encouraged to contact the Company at:

https://www.vesaliuslabs.com/

For further information, please refer to the Company’s disclosure record on SEDAR+ at www.sedarplus.ca.

On Behalf of the Company

“Pradeep Albert”
Chief Executive Officer

Contact

Julia Becker
Vice President, Capital Markets
T: +1 (604) 785-0850
E: jbecker@vesaliuslabs.com

View the official press release (opens in a new tab)
Disclosure

This article is for informational purposes only. It does not constitute medical, legal, or investment advice. Vesalius Longevity Labs products are intended for licensed healthcare providers.

The CSE has neither approved nor disapproved the contents of this press release.

Disclaimer: The information provided on this website is intended for general educational and informational purposes only. Vesalius Longevity Labs provides information relating to peptide science, longevity, wellness, metabolic health, and emerging areas of medical research.

FDA Approval & Investigational Therapies: Not all peptides, compounds, medications, or therapies discussed or referenced on this website are approved by the U.S. Food and Drug Administration (FDA). Certain compounds may be investigational, have limited clinical evidence, or lack established long-term safety and efficacy data. References to scientific research, emerging therapies, or potential health benefits are provided for informational purposes and should not be interpreted as claims of FDA approval, established clinical effectiveness, or guaranteed therapeutic outcomes. Where legally permitted, certain medications may be compounded by appropriately licensed pharmacies in accordance with applicable federal and state laws. Compounded medications are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before marketing in the same manner as FDA-approved medications. Read the full disclaimer.